SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (424)4/26/1999 3:53:00 PM
From: Dave Sullivan  Read Replies (2) of 712
 
While almost any of the smaller an med sized biotech co. are potential merger partners there are a number of characteristics that make some more likely cnadidates than others. First if the stock is undervalued this is good Second if the company has products close to market Thirdly if the companys products fit well with the acquiring company all of these appyly to corr. They have a product on the market,moving rapidly to profitability, and their focus on cardiovascular disease is attractive to a company like Chiron, also note Chiron's Chief Scientific Officer was the scientific founder of corr. We can not find words strong enongh to tell you how much we love the stock at these prices (8 5/8) Buy all the way to 18 with a target of 50.

This is a adlib from a article I read in Dick Davis Digest

Dave
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News